Sparc-Like Protein 1 Is a New Marker of Human Glioma Progression

Turtoï, Andrei; Musmeci, Davide; Naccarato, Antonio Giuseppe; Scatena, Cristian; Ortenzi, Valerio; Kiss, Róbert; Murtas, Daniela; Patsos, Georgios; Mazzucchelli, Gabriel; Pauw, Edwin De; Bevilacqua, Generoso; Castronovo, Vincenzo

doi:10.1021/pr3005698

Cited by 29 publications

(23 citation statements)

References 44 publications

(60 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Abnormal expression of the SPARCL1 gene and protein have been reported during the development and progression of many types of cancer, including non-small cell lung carcinomas [23], prostate carcinoma [24], colorectal carcinoma [14-17], gastric cancer [18, 19], pancreatic cancer [9], hepatocellular carcinoma [5], osteosarcoma [25] and gliomas [26]. The diverse expression pattern of SPARCL1 in different human malignancies suggests that it might play different roles in tumor biology based on the tumor type [2].…”

Section: Discussionmentioning

confidence: 99%

SPARCL1, a Novel Prognostic Predictive Factor for GI Malignancies: a Meta-Analysis

Cui

Zheng

et al. 2017

Cell Physiol Biochem

View full text Add to dashboard Cite

Background/Aims: Secreted protein acidic and rich in cysteines-like 1 (SPARCL1) is abnormally expressed in gastrointestinal (GI) malignancies. However, the correlation between SPARCL1 expression and the prognosis of patients remains unknown. Therefore, we performed a meta-analysis to investigate the potential value of SPARCL1 as a prognostic predictive marker for GI malignancies. Methods: The PubMed, Embase, EBSCO, CNKI, and Wanfang databases were systematically searched for studies examining SPARCL1 and clinicopathological features, including the prognoses of patients. Hazard ratios (HRs) and odds ratios (ORs) from individual studies were calculated and pooled using a random-effects or fix-effects model. Heterogeneity and publication bias analyses were performed. Results: Data from 8 studies, including a total of 2,356 patients, were summarized. The expression of SPARCL1 suggested a better prognosis (HR=0.57, 95% CI: 0.445-0.698, P=0.000) and was associated with clinicopathological features of GI malignancies, including distant metastasis (OR=0.44, 95% CI: 0.23-0.85, P=0.014), lymph node metastasis (OR=0.56, 95% CI: 0.39–0.81, P=0.002) and tumor differentiation (OR=2.21, 95% CI: 1.82–2.69, P=0.000). Subgroup analyses based on cancer type revealed that the expression of SPARCL1 had no effect on lymph node metastasis in colorectal cancer, and it did not influence tumor differentiation in gastric cancer. Egger’s test showed no evidence of publication bias (all P>0.05). Conclusion: SPARCL1 could be a novel prognostic predictive factor for GI malignancies. The expression of SPARCL1 could influence the clinicopathological features of GI malignancies. Further large-scale studies are essential to confirm SPARCL1’s prognostic predictive value, and more fundamental experimental studies are needed to illustrate the mechanisms.

show abstract

Section: Discussionmentioning

confidence: 99%

SPARCL1, a Novel Prognostic Predictive Factor for GI Malignancies: a Meta-Analysis

Cui

Zheng

et al. 2017

Cell Physiol Biochem

View full text Add to dashboard Cite

show abstract

“…HOXD8 is known to be methylated and/or down-regulated in human malignancies, especially in metastatic, rather than in primary lesions 36,3738,3940.…”

Section: Discussionmentioning

confidence: 99%

Epigenetic clustering of lung adenocarcinomas based on DNA methylation profiles in adjacent lung tissue: Its correlation with smoking history and chronic obstructive pulmonary disease

Sato

Arai²,

Kohno

et al. 2014

Int. J. Cancer

View full text Add to dashboard Cite

The aim of this study was to clarify the significance of DNA methylation alterations during lung carcinogenesis. Infinium assay was performed using 139 paired samples of non-cancerous lung tissue (N) and tumorous tissue (T) from a learning cohort of patients with lung adenocarcinomas (LADCs). Fifty paired N and T samples from a validation cohort were also analyzed. DNA methylation alterations on 1,928 probes occurred in N samples relative to normal lung tissue from patients without primary lung tumors, and were inherited by, or strengthened in, T samples. Unsupervised hierarchical clustering using DNA methylation levels in N samples on all 26,447 probes subclustered patients into Cluster I (n = 32), Cluster II (n = 35) and Cluster III (n = 72). LADCs in Cluster I developed from the inflammatory background in chronic obstructive pulmonary disease (COPD) in heavy smokers and were locally invasive. Most patients in Cluster II were non-smokers and had a favorable outcome. LADCs in Cluster III developed in light smokers were most aggressive (frequently showing lymphatic and blood vessel invasion, lymph node metastasis and an advanced pathological stage), and had a poor outcome. DNA methylation levels of hallmark genes for each cluster, such as IRX2, HOXD8, SPARCL1, RGS5 and EI24, were again correlated with clinicopathological characteristics in the validation cohort. DNA methylation profiles reflecting carcinogenetic factors such as smoking and COPD appear to be established in non-cancerous lung tissue from patients with LADCs and may determine the aggressiveness of tumors developing in individual patients, and thus patient outcome.

show abstract

“…accrued on mice. 26 The absence of proteins in normal human tissues was confirmed by analyzing publicly deposited DNA microarray (www.biogps.org) and IHC data (www.proteinatlas. org).…”

Section: Ms Data Analysismentioning

confidence: 99%

Accessibilome of Human Glioblastoma: Collagen-VI-alpha-1 Is a New Target and a Marker of Poor Outcome

et al. 2014

Self Cite

View full text Add to dashboard Cite

Functional targeted therapy has unfortunately failed to improve the outcome of glioblastoma patients. Success stories evidenced by the use of antibody−drug conjugates in other tumor types are encouraging, but targets specific to glioblastoma and accessible through the bloodstream remain scarce. In the current work, we have identified and characterized novel and accessible proteins using an innovative proteomic approach on six human glioblastomas; the corresponding data have been deposited in the PRIDE database identifier PXD001398. Among several clusters of uniquely expressed proteins, we highlight collagen-VI-alpha-1 (COL6A1) as a highly expressed tumor biomarker with low levels in most normal tissues. Immunohistochemical analysis of glioma samples from 61 patients demonstrated that COL6A1 is a significant and consistent feature of high-grade glioma. Deposits of COL6A1 were evidenced in the perivascular regions of the tumor-associated vasculature and in glioma cells found in pseudopalisade structures. Retrospective analysis of public gene-expression data sets from over 300 glioma patients demonstrated a significant correlation of poor patient outcome and high COL6A1 expression. In a proof-of-concept study, we use chicken chorioallantoic membrane in vivo model to show that COL6A1 is a reachable target for IV-injected antibodies. The present data warrant further development of human COL6A1 antibodies for assessing the quantitative biodistribution in the preclinical tumor models.

show abstract

Sparc-Like Protein 1 Is a New Marker of Human Glioma Progression

Cited by 29 publications

References 44 publications

SPARCL1, a Novel Prognostic Predictive Factor for GI Malignancies: a Meta-Analysis

SPARCL1, a Novel Prognostic Predictive Factor for GI Malignancies: a Meta-Analysis

Epigenetic clustering of lung adenocarcinomas based on DNA methylation profiles in adjacent lung tissue: Its correlation with smoking history and chronic obstructive pulmonary disease

Accessibilome of Human Glioblastoma: Collagen-VI-alpha-1 Is a New Target and a Marker of Poor Outcome

Contact Info

Product

Resources

About